MENU
 
  Saturday, February 11, 2012
Market Day
Company News
Finance
Home
Health
Dieting
Gifts
Software
Insurance
Recent

Topeka KS Singles
Topeka KS Auto Insurance
Topeka KS Satellite TV
Ims Health News
Mylan gets US FDA final approval for generic Doryx tablets
pharmabiz.comDoxycycline hyclate DR tablets had US sales of approximately $264.1 million for the 12 months ending December 31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, ...

SwedishAmerican named one of most integrated in U.S.
Rockford Register StarBy Anonymous SwedishAmerican Health System was named one of the nation's 100 most integrated health care networks by IMS Health, a consulting firm that analyzes the progress of local and regional non-specialty integrated health care networks.

Mylan Receives Final FDA Approval for First Generic Version of Doryx Tablets ...
Benzinga31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...

Mylan Receives Final FDA Approval for First Generic Version of Doryx® Tablets ...
Sacramento Bee31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...

Mylan Receives Final FDA Approval for First Generic Version of Doryx Tablets ...
Citybizlist (press release)31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...

Mylan Receives Final FDA Approval for First Generic Version of Doryx® Tablets ...
MarketWatch (press release)31, 2011, according to IMS Health. Currently, Mylan has 173 ANDAs pending FDA approval representing $98.3 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.6 ...

Alchemia-Update On Fondaparinux Sales
PT NewsThe latest weekly data from US IMS Health shows that Dr Reddy's generic fondaparinux reported prescription market share of 18%. This represents recent sales in excess of $1.4m per week. The retail segment of the market (non-hospital) is known to be ...



Copyright © 2004-2011 Market-Day.net
All rights reserved.